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Nephrolithiasis in the communities of Northeast Thailand frequently presents with multiple
chronic health complaints, i.e. myofascial pain, back pain, dyspepsia, arthralgia, headache,
fatigue, frank paresthesia, dysuria and any of these aggravated by purine-rich food (PRF).
We assessed the efficacy of Orthosiphon in treating subjects with at least two active symptoms
and negative for urine white blood cells. Subjects were randomly allocated to two groups.
Crude extract of Orthosiphon given in a capsule (equivalent to 1.6–1.8g of dried leaves of
Orthosiphon) two times a day to Group 1 (n=36) and a placebo to Group 2 (n=40) for
14 days. The medication for each subject was packed and its code kept secret until the data
analysis. Both groups were asked not to consume any of 25 purine-rich foods (PRFs) during
treatment. The primary measure was the reduced sum of active severity symptoms as recorded
using the visual analog scale before and after therapy (i.e. on day 7 and 14). The data on
76 subjects were processed. The mean of the total scores (95% CI) of the symptoms in each
group were decreased significantly (P<0.001); 185.6 (153.3, 218.0) to 94.7 (58.2, 131.2) in the
Orthosiphon group and 196.1 (164.4, 227.8) to 89.6 (62.8, 116.5) in the placebo group. When
comparing between groups, no statistically significant difference was found. The mean
consumption in PRFs was significantly decreased (P<0.001) in both groups; however,
Orthosiphon did not have additional benefit over placebo at 7 and 14 days of treatment during
which they reduced these foods.
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Introduction
Nephrolithiasis is a common health problem among
the rural dwellers of Northeast Thailand. The prevalence
of stone cases varies between reports according to the
instruments used (range 0.38–16%) (1,2). Besides having
kidney stones, affected persons have multiple chronic
health complaints (MCHCs): (i) myofascial pain; (ii) back
pain; (iii) dyspepsia; (iv) arthralgia; (v) headaches;
(vi) fatigue; (vii) frank paresthesia; (viii) dysuria and,
(ix) any of these symptoms are aggravated by drinking
alcoholic beverages or eating fermented or purine-rich
foods (PRFs) (3). These complaints (i.e. dyspepsia,
myofascial pain, back pain, arthralgia) are among the
common complaints in the out-patient departments
(OPDs) of the sub-district health centers and community
hospitals. Due to limited resources, patients are treated
according to their symptoms and thus likely to revisit,
leading to overcrowded OPDs.
A recent survey showed that 93.4% of rural dwellers
consumed bamboo shoots or some PRF at least once a
week and the prevalence of aggravated symptoms by
PRF was 43.3% (4). Searching for an effective treatment
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properly cited.of MCHC is essential for the patient as well as for
reducing the workload at health centers. In another
study, patients with kidney stones with MCHC, positive
for white blood cells in the urine, were treated with
antibiotics for 2 months plus Orthosiphon grandiflorus
(OG) or sodium potassium citrate according to the
treatment groups. More than 90% of both groups
reported a dramatic reduction in symptoms (i.e. myofas-
cial pain, arthralgia, dyspepsia and fatigue) without other
pharmaceutical products (3). Similarly, Nirdnoy and
Muangman (5) observed that drinking an infusion (tea)
made from OG caused an increase in urinary pH and the
tendency to increase excretions of both K and citrate.
They questioned whether the outcome was the effect of
the antibiotic or the OG via a correction of K and citrate
which are depleted in Northeast Thais suffering from
nephrolithiasis (6).
Plant-based systems continue to play an essential role
in the primary healthcare of 80% of the world’s
population. Several of the effective anticancer agents in
current use are derived from nature. The search for novel
antitumor agents from natural sources is ongoing
with botanists, marine biologists and microbiologists
teaming up with chemists, pharmacologists, toxicologists
and clinicians in the investigation of coral reefs, rain-
forests for novel bioactive compounds. Over 50% of the
anticancer drugs approved by the United States
Food and Drug Administration since 1960 originally
derived from natural resources, especially from terrestrial
plants (7).
Recently, much attention has been directed toward
extracts and biologically active compounds extracted
from popular plant species. The aqueous extract of
leaves of Indigofera suffruticosa obtained by infusion
showed strong inhibitory activity against Staphylococcus
aureus, Trichophyton rubrum and Microsporum canis.
This study suggests that the aqueous extracts of leaves
can be used in the treatment of skin diseases caused by
dermatophytes (8). An in vitro study showed that
an aqueous extract of Orthosiphon aristatus has an anti-
bacterial activity against two serotypes of Streptococcus
mutans (MIC 7.8–23.4mg/ml) (9). Another study
revealed that Orthosiphon stamineus extract inhibited
spore-germination in six of nine fungal species tested
(viz. Saccharomyces pastorianus, Candida albicans,
Rhizopus nigricans, Penicillium digitatum, Fusarium oxy-
sporum and Trichophyton mentagrophytes) (10).
Orthosiphon is found throughout Southeast Asia. It is
called ‘java tea’ in Indonesia and ‘Yha Nhuard Maw’ (cat’s
whiskers) in Thailand. It grows to about 1m in height and
produces white to light-violet flowers. Orthosiphon has
been used as herbal tea for centuries in Southeast Asian
countries. Traditionally, it is used to treat gout, rheuma-
tism, diabetes, hypertension and renal stones.
Side effects of Orthosiphon are rare. According to
the Thai traditional medicine, the people believe that the
Orthosiphon infusion may have high concentration of
potassium and should not be used in the patients with
concurrent cardiac diseases.
This study aimed to evaluate the effect of OG versus a
placebo for the treatment of nephrolithiasis in patients
suffering from MCHC and testing negative for white
blood cell in the urine.
Materials and Methods
Trial Design, Funding and Ethics Approval
Our study was a prospective, concealed, randomized,
controlled trial conducted over a 2-week period. The
research was supported by Khon Kaen University and
the protocol was approved by the Ethics Committee of
Khon Kaen University (HE 471224). Written, informed
consent was obtained from the patients who met the
inclusion criteria.
Patients
Free, ultrasound checks for renal stones were announced
through local health workers and village headmen in 15
villages. Participants joining the study were interviewed
for their chronic health complaints, received an ultra-
sound examination and underwent urinalysis (using a
urine strip). All of the subjects were asked about the
presence of nine chronic symptoms: (i) multiple myofas-
cial pain; (ii) back pain or lower abdominal pain;
(iii) dyspepsia; (iv) poly-arthralgia; (v) single-side head-
ache; (vi) fatigue; (vii) frank paresthesia; (viii) dysuria at
least once a year and, (ix) any of these symptoms were
aggravated by PRF.
The inclusion criteria comprised: (i) patients with renal
stones or having a hyperechoic focus suspected of being a
stone; (ii) having five or more of the nine variables of
MCHC; (iii) having at least two active symptoms and,
(iv) being between 20 and 65 years of age. Subjects were
excluded if they had: (i) a stone obstruction; (ii) heart
disease; (iii) known chronic renal failure; (iv) were preg-
nant or, (v) had any other severe illness. Patients with
white blood cells in the urine, using a strip read by
a portable urine analyzer (UriluxS, Roche, Basel,
Switzerland), were also excluded from this study but
entered into another.
Randomization
Subjects were stratified by the number of their
active symptoms: those with two–four symptoms were
assigned to Group A, and those with more than four
symptoms to Group B. In each group, running numbers
were listed according to the time sequence, viz. A01, A02,
A03,..., A50 in Group A and B01, B02, B03, ...,B50 in
Group B.
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(the OG group) or G2 (the placebo group) by block of
six. For example, every six consecutive participants were
enrolled in each group (A, B), three subjects by coin toss to
the OG group and three to the placebo group. Thus, each
running number in each subgroup belonged to the code of
either OG or placebo. The medication was prepared
according to the code. Thereafter, the codes were concealed
and not opened until the data analysis phase.
Treatment
The placebo and OG extract were filled into identical-
looking capsules. The placebo contained the dried ground
vegetable Ipomoea Aquatica Forsk. To prepare the OG
extract, dried leaves of OG were ground in a mechanical
mill and put in hot water (kept at 70–80 C for 20min.
The infusion was separated in a container and put on a
water bath. The temperature of the infusion was kept at
70–80 C for 36h until it nearly dried then it was mixed
with a prepared mixture, and left in the chamber for
48–72h at 40–50 C until dried. This dried mixture was
ground and capsules filled with it. Each capsule of OG
extract equaled 1.6–1.8g of the dried leaves.
Therapies consisted of 20minute health education for
the MCHC and encouraged them to stop consuming the
25 PRF items during the trial period. Group 1 took one
capsule of OG two times a day while Group 2 took the
placebo.
The Adverse Effects of Treatments
Adverse effects in this study were defined as: any new
symptoms that occurred during treatment, or old, inac-
tive symptoms which became active during treatment.
The Purine-Rich Foods
PRFs in this study included: bamboo shoot (Gigantochloa
albociliata, Bambusasp., Thysostachys siamensis Gamble),
tops of Calamus rotang Linn; leaf shoot of coconut
(Cocos nucifera Linn); young leaves of Acacia pennata;
common local mushrooms [Pleurotus sajor-caju (Fr.)
Singer, Lentinus squarrosulus Mont., Volvariella volvaceae,
Termitomyces fuliginosus Heim]; fermented boiled flour in
noodle form; all kinds of fermented fruits or vegetables;
alcoholic beverage; grasshoppers [Locusta migratoria
manilensis (Meyen), Patanga succincta (Linnaeus)]; queen
or larva of red ant (Oecophylla smaragdina); silk worm
(Philoamia ricini Boisd); all kinds of crickets (Acheta
testacea, Acheta bimaculatus De Geer, Bracytrupes por-
tentosus Licht.); beef or buffalo meat (Swamp buffalo);
a local small freshwater fish (Rasbora tornieri); shellfish
(Sinotaia ingallsiana, Pila polita); cuttlefish (Sepia phar-
aonis); squid (Loligo peali); chicken (G.gallus domesticus);
duck (Anseriformes anatidae); adult, small /larva of frog
(Rana tigerina) and ricefield rat (Rattus argentiventer).
Measurements
The main outcome measure was the sum of score of each
patient’s active symptoms on the visual analog scale
(VAS). Each symptom had a maximum score of 100 and
a minimum score of 0. The VAS was performed by each
patient under supervision at the beginning (on day 0) and
upon follow up (at day 7 and 14). The second outcome
was the score on the general feeling of illness. Data on
daily PRF intake were collected, retrospectively, through
interviews on days 0, 7 and 14.
Data Analysis
Data were expressed as means and 95% confidence
intervals (95% CI), medians and inter-quartile ranges
(IQRs). A comparison of results between groups was
performed using unpaired t-tests for normal distributions
or the Mann–Whitney U-test for skewed distributions.
Before and after within groups analyses were done using
the paired t-test or the Wilcoxon signed ranks test (WSRT)
for normal or skewed distributions, respectively. A prob-
ability of P<0.05 was considered statistically significant.
Results
Eighty-seven subjects agreed to participate in the study, of
whom six in the OG and five in the placebo group were lost.
Four subjects in the OG declined to join because of the
adverse effects: dizziness, myofascial pain, fatigue and
palpitation. Two subjects from the OG group and three
from the placebo group felt unchanged and quit in the
second week. Two subjects in the placebo group moved out
of province and we lost contact with them. Seventy-six
subjects had complete data portfolios and were analyzed,
on an intention to treat basis. (Fig. 1).
Enrollment (n=87)
meeting inclusion
criteria, willing stop PRF 
active symptoms 
2-4= A;  >4 = B
Gr A=44 Gr B=43
Randomizatio n [block
of 6]
Follow up
Lost to follow up (n=6) Lost to followup
(n=5)
Analysis
OG (n=42) Placebo (n=45)
Allocation
Analyzed
(n=36)
Analyzed
(n= 40)
Figure 1. Details of MCHC patients enrolled in the study.
eCAM 2009;6(4) 497Baseline Patient Characteristics
The mean age of the 76 participants was 53.7 years
(55.6 for OG and 53.8 for placebo); 36 were in the
OG group and the 40 in placebo group. Table 1
shows the patients’ baseline characteristics by treatment
groups, which were similar. Most of the participants were
women (64.5 and 67.5%) over 45 years of age
(80.0 and 80.0%, respectively). In the OG and placebo
groups, the respective mean (95% CI) of the MCHC
variables was 6.7 (6.1, 7.9) and 7.5 (6.7, 7.3), and
of active symptoms (95%CI) 3.8 (3.3, 4.2) and 4.1
(3.6, 4.7). For the OG and placebo groups, respective
renal stone detection was 71.0 and 80.6% and for red
blood cells (RBCs) in the urine 25.7 and 17.5%.
The positive history for symptoms aggravated by PRF
was 79.1 and 94.7%, respectively. The mean (95% CI)
VAS score for general feeling of illness between the OG
and placebo groups was 52.6 (47.2, 58.0) and 50.3
(42.5, 58.1), respectively. For total MCHC symptoms,
the respective mean (95%CI) VAS score for the OG
and placebo groups was 185.6 (154.4, 216.8) and 196.1
(163.7, 228.5) points.
Main Outcomes: Sum of VAS Scores of MCHC
In the OG group, the median (IQR) of the sum of
VAS scores of the MCHC symptoms was 109.5 (114.3)
at day 7 and 68.0 (125.8) at day 14, which were
significantly decreased (P-value<0.001, WSRT) from
the value on day 0 [166.5 (130.8)] (Table 2). The
respective mean (95% CI) sum of VAS scores on day 7
and 14 was 119.0 (88.3, 149.7) and 94.7 (58.2, 131.2),
which was 64.1 and 51% of the value on day 0 [185.6
(153.3, 218.0)].
In the placebo group, the median (IQR) of the sum of
VAS scores for MCHC symptoms was 101.5 (119.0) on
day 7 and 79.5 (94.7) on day 14, significantly decreased
(P-value<0.001, WSRT) from the beginning [186.5
(104.5)] (Table 3). The respective mean (95% CI) of the
sum of VAS scores on day 7 and 14 was 129.6 (100.0,
159.3) and 89.6 (62.8, 116.5), which was 66.1 and 45.7%
of the value before treatment.
There was no statistically significant difference for the
OG versus placebo groups for the beginning, day 7 and
day 14 of treatment (Table 3). Instead, in both groups,
each symptom of the MCHC, as a VAS score, at day 7
and 14 was significantly decreased (P-value<0.05,
WSRT) from day 0. Figure 2 illustrated the VAS scores
at day 0, 7 and 14 for myofascial pain, arthralgia,
dyspepsia and back pain.
The General Feeling of Illness
In the OG group, the median (IQR) of the VAS scores
for the general feeling of illness was 34 (20.8) at day 7
and 27 (37.5) at day 14, both significantly decreased
Table 2. VAS scores of general feeling of illness for 76 patients by
treatments
Group VAS score of general feeling of illness
Day 0 Day 7 Day 14
OG
a (n=36) Median (IQR
b) 50 (12.8) 34 (20.8)* 27 (37.5)*
Mean (SD) 52.1 (16.4) 35.5 (18.9) 31.3 (24.5)
95% CI 46.5,57.5 29.1,41.9 22.9,39.5
Placebo Median (IQR) 50.0 (35.0) 32.0 (44.0)* 15 (38.0)*
(n=40) Mean (SD) 50.3 (24.1) 36.5 (24.1) 26.2 (24.4)
95% CI 42.5,58.2 28.7,44.3 18.3,34.1
P-value
§ 0.779 0.928 0.374
aOrthosiphon grandiflorus;
bInter-quartile range.
*P<0.001 compare before and after by Wilcoxon Signed Ranks.
§Compared between groups by Mann-Whitney U.
Table 3. Total VAS scores of MCHC for 76 patients by treatments
Group Total VAS scores
Day 0 Day 7 Day 14
OG Median (IQR
a) 166.5 (130.8) 109.5 (114.3)* 68.0 (125.8)*
(n=36) Mean (SD) 185.6 (95.6) 119.0 (90.7) 94.7 (107.9)
95% CI 153.3,218.0 88.3,149.7 58.2,131.2
Placebo Median (IQR) 186.5 (104.5) 101.5 (119.0)* 79.5 (94.7)*
(n=40) Mean (SD) 196.1 (99.2) 129.6 (92.7) 89.6 (83.9)
95% CI 164.4–(227.8) 100.0–159.3 62.8–116.5
P-value
y 0.747 0.689 0.791
aInterquartile range.
*P<0.001, comparing before and after by Wilcoxon Signed Ranks.
yCompared between groups by Mann–Whitney U.
Table 1. Baseline characteristics and mean scores by VAS scale for 76
patients
Characteristic OG
a gr.
(n=36)
Placebo
(n=40)
P-value
Age (>45) 29 (80.0%) 32 (80.0%) 0.95
y
Sex (female) 22 (64.5%) 27 (67.5%) 0.56
y
Renal stone positive 22 (71.0%) 29 (80.6%) 0.36
y
Urine red blood cell
positive
9 (25.7%) 7 (17.5%) 0.39
y
Aggravated by
PRF
b
27 (79.1%) 36 (94.7%) 0.08
y
No. of MCHC
c
mean(95%CI)
6.7 (6.1,7.9) 7.5 (6.7,7.3) 0.22
z
No. of Active sym.
mean (95%CI)
3.8 (3.3,4.2) 4.1 (3.6,4.7) 0.31
z
Gen feeling mean
(95%CI) of VAS
52.6 (47.2,58.0) 50.3 (42.5,58.1) 0.71
z
MCHC
d mean
(95%CI) of VAS
185.6 (154.4,216.8) 196.1 (163.7,228.5) 0.64
z
aOrthosiphon grandiflorus;
bPurine rich food;
cMultiple chronic health
complaint;
dSum of VAS scores of MCHC.
yChi-square tests.
zMann–Whitney test U.
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The respective mean (95% CI) of the VAS scores for the
general feeling of illness on day 7 and 14 was 35.5 (29.1,
41.9) and 31.3 (22.9, 39.5), which was 68.1 and 60.1% of
the value in day 0 [52.1 (46.5, 57.5)].
In the placebo group, the median (IQR) of the sum of
VAS scores of the general feeling of illness was 32.0 (44.0)
on day 7 and 15 (38.0) on day 14, both significantly
decreased (P-value<0.001, WSRT) from the beginning
[50.0 (35)] (Table 3). The respective mean (95% CI) of the
sum of VAS scores of the general feeling of illness on day 7
and 14 was 36.5 (28.7, 44.3) and26.2 (18.3, 34.1), which was
72.6% and 52.1% of the value before treatment [50.3 (42.5,
58.2)]. There was no significant difference between groups
in the VAS scores on the general feeling of illness on days 7
and 14 of treatment.
Adverse Effects
The adverse effects in the first and second week of
treatments were 27.8 and 2.8% for the first and the
second week in the OG group, and 17.5 and 17.5% in the
placebo group for the first and the second week,
respectively (Table 4). There was a significantly difference
(P=0.03, Fisher exact Chi-Squared) when compared
between groups in the second week. When compared
within the same group at the first and second week, the
reported adverse effects were reduced significantly in the
OG group (P<0.01, WSRT). The adverse effects
reported during the treatments included myofascial,
fatigue, back pain, abdominal pain, arthritis, gastro-
intestinal disturbance and headache; most of which are
the symptoms included in the MCHC variables, but were
inactive in the pretreatment period.
Purine Rich Foods
The frequencies of PRF consumptions over the seven
previous days were reviewed retrospectively at the
beginning of the trial and when the subjects came to
follow up on day 7 and 14. Table 5 shows the median
(IQR) and mean (95%CI) of PRF consumption the week
before treatment and during the first and the second
week of treatment.
In the OG group, the mean frequency of consumption
of bamboo shoot and of the 25 kinds of PRF before
treatment was 3.9 and 14.2 times/person/week but this
dropped to 0.1 and 1.3 times 0.1 and 1.3 times/person/
week during the first and second weeks, respectively.
For the placebo group, the respective mean frequency
of eating bamboo shoots and the other kinds of PRFs
was 3.6 and 11.4 times/person/week in the week before
treatment and 0.4 and 0.9 times and 0.1 and 0.7 times/
person/week during the first and second week,
respectively.
Both groups significantly (P<0.001, WSRT) reduced
the intake of PRFs during the first and second week to
<10% of the frequencies before treatment. There was no
significant difference in the frequencies of PRF consump-
tions between groups during the first and second weeks
of treatment (Table 5).
Discussion
This study was a double blind, randomized control trial
with strict concealment, and it was the first to reveal a
method of treating MCHC as a syndrome, the common
presentation among the rural dwellers of Northeast
Thailand. These groups of patients had renal stones
(mostly small) or suspected of having stones, detected as
hyperechoic foci on ultrasonography. All of the partici-
pants were negative for white blood cells in the urine.
0
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Figure 2. VAS scores of myofascial pain dyspepsia arthralgia back pain
of OG, placebo group on day 0, 7 and 14 of treatment.
Table 4. Reported adverse effects in the first and second week of
treatments
Adverse effect and details OG
a gr. (n=36) Placebo gr.(n=40)
Day
0–7
Day
8–14
Day
0–7
Day
8–14
Reported adverse effects 10 (27.8%)** 1 (2.8)* 7 (17.5) 7 (17.5)*
Details
b Myofascial 3 1 4 1
Fatigue 4 0 2 1
Back/abdominal pain 2 1 0 2
Arthritis 1 0 1 0
Sleep problem 2 0 1 0
Gastrointestinal
disturbance
10 1 3
Headache 0 0 1 0
Others
c 00 0 3
aOrthosiphon grandiflorus;
bA subject had 1 symptoms;
cParesthesia,
urticaria, and dizziness.
*P=0.03 by Fisher exact Chi-Square.
**P<0.01 compared within group by Wilcoxon Signed Ranks Test.
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the severity of the symptoms to approximately one-half
by the end of the second week of treatment. When PRF
consumption was restricted, the OG (3.2–3.6g/day) did
not have any additional benefit over placebo in the
treatment of MCHC symptoms at day 7 or 14 after
treatment. This suggests that when the rate of uric
acid, or other waste compound, production was low, OG
did not have additional benefit over placebo for the
excretion.
People suffering from joint pains and myofascial pain feel
better when they use Orthosiphon, even when they do not
restrict any particular kinds of food. Accounts of this
experience are anecdotal but have been reported in many
countries for a long time. One study (3) indicated that when
the authors did not ask for PRF restrictions, both OG plus
antibiotic and sodium potassium citrate plus antibiotic
dramatically reduced the MCHC symptoms associated
with nephrolithiasis among patients positive for urine white
blood cells. This information plus the data from our
present study suggests: (i) Orthosiphon can reduce the
symptoms even when there are no restrictions on the types
of food eaten and, (ii) when consumption of PRFs are
restricted, Orthosiphon does not have any additional effect
over placebo.
Some foods (i.e. grasshoppers, red ant larvae, silk-
worms, crickets, bamboo shoots, frogs and their larvae
and ricefield rats) are unfamiliar to people in other parts
of the world, but for the rural, subsistence dwellers of
Northeast Thailand, these foods are common. Data from
a random survey in the rural communities in Khon Kaen
revealed that during 1 week, more than 9 out of 10
persons consumed at least once of the following PRF:
bamboo shoot, fermented food, meat or insects; and 4
out of 10 reported having their symptoms aggravated by
these foods (4). Most of the 25 kinds of restricted foods
in the study, PRFs as well as the fermented foods and
alcoholic beverages, usually cause pain in patients
diagnosed as gout.
Restriction of the foods over our 2-week research
period was practicable for the 76 participants, but it
would not be easy to maintain compliance for much
longer (and certainly not lifelong) without repeated
education and public health information. Nevertheless,
the study indicates that MCHC patients could relieve
their own problems if they decided to restrict particular
kinds of foods.
In order to create effective management guidelines
for MCHC patients, further research should focus on:
(i) will the symptoms completely disappear if the PRF
restrictions are prolonged? (ii) Can the OG significantly
relieve MCHC symptoms more than the placebo in
patients who do not restrict PRF intake? (iii) What is
the precise mechanism relating this effect to MCHC
variables? (iv) What is the regional variation in the
prevalence of MCHC and its association with PRF intake
in communities with a different prevalence of renal
stones?
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